Molecular residual disease: Charting a new path for treating resectable solid tumors.

Detection of molecular residual disease via circulating tumor DNA identifies high recurrence risk in resectable solid tumor patients, enabling more efficient clinical trials.

• Why it matters: Current methods lack precise tools to stratify patients post-surgery, limiting the ability to tailor treatments and accelerate therapy development for solid tumors.
• What they did: An MRD Registry was proposed to combine ctDNA measurements with patient outcomes, serving as an external control to validate ctDNA dynamics as indicators of treatment response.
• The result: This approach promises to improve trial efficiency by enabling targeted patient enrichment and supports faster development of personalized therapies for resectable solid tumors.